Although renal denervation didn’t go down so well for the management of refractory hypertension, that doesn’t mean the problem has gone away. This new randomised controlled trial is about trying something a little different – and the early results look promising. Check it out at the Lancet, here.
The recent AHA meetings have provided a littany of articles to look at, with the most recent coming in an online first form over at the New England Journal of Medicine. This topic however has been looked at before (ASTRAL and STAR), and now this new trial titled CORAL aims to put the argument to bed once and for all. Continue reading
ACE inhibitors are the first line drug for control of hypertension in diabetics, with a plethora of benefits including the reduction of proteinuria. The follow on question then is whether adding an A2 receptor blocker will help further – and this article gives you the answer.
For acute blood pressure control in pregnancy, different hospitals often have different guidelines. Hydralazine used to be all the rage but fell out of favour after a concerning safety profile was highlighted. Intravenous labetalol is commonly used, but many also consider nifedipine first line. This double blind randomised controlled trial from India aims to settle the issue.
Chronic kidney disease is now becoming increasingly common, particularly in the early stages, mainly due to a combination of hypertension and diabetes. The ACP have put together a lovely evidence based guideline to get on top of the management of CKD, including the following recommendations.